 |
Quick Links |
| Information by Disease |
|
|
|
| Cancer News |
|
|
|
| Conference Coverage |
|
|
|
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
|
|
Malignant Mesothelioma - General
|
|
Trimodality Therapy May Improve Outcomes of Patients with Pleural Mesothelioma (7/14/2009)
Researchers involved in a multi-center U.S. trial have reported neoadjuvant chemotherapy with Alimta® (pemetrexed) and Platinol® (cisplatin), followed by pneumonectomy and radiation therapy, may improve survival of patients with Stage I-III pleural malignant mesothelioma. The details of this study appeared in the June 20, 2009 issue of the Journal of Clinical Oncology.
Alimta® with or Without a Platinum Compound Confirmed Effective Palliation for Peritoneal Mesothelioma (4/9/2009)
Researchers from Italy have reported that Alimta® (pemetrexed), with or without a platinum compound, is active and well tolerated in patients with peritoneal mesothelioma. The details of this study appeared in the May 1, 2009 issue of Lung Cancer.
Alimta® plus Paraplatin Effective Palliation for Pleural Mesothelioma (4/8/2009)
Researchers from the United Kingdom have reported that Alimta® (pemetrexed) and Paraplatin® (carboplatin) may be effective palliation for patients with malignant pleural mesothelioma. The details of this study appeared in the May 1, 2009 issue of Lung Cancer.
Alimta® and Gemzar® Effective for Peritoneal Mesothelioma (7/22/2008)
Researchers affiliated with a multicenter U.S. trial have reported that the combination of Alimta® (pemetrexed) and Gemzar® (gemcitabine) was active in patients with peritoneal mesothelioma. The details of this study appeared in the July 20, 2008 issue of the Journal of Clinical Oncology.
Navelbine® and Platinol® Effective for Mesothelioma (7/10/2008)
Researchers from Denmark have reported that the combination of Navelbine® (vinorelbine) and Platinol® (cisplatin) is highly active in patients with newly diagnosed non-resectable malignant pleural mesothelioma. The details of this study appeared in an early online publication in the British Journal of Cancer on June 10, 2008.
Alimta® and Paraplatin® Effective in Elderly with Mesothelioma (7/9/2008)
Researchers from Italy have reported that the combination of Alimta® (pemetrexed) and Paraplatin® (carboplatin) is effective palliative therapy for elderly patients with mesothelioma. The details of this study appeared in an early online publication in the British Journal of Cancer on June 10, 2008.
Chemotherapy May Not Affect Survival or Quality of Life for Patients with Advanced Mesothelioma (5/21/2008)
Researchers from the UK and Australia involved in a multicenter randomized trial have concluded that chemotherapy for advanced pleural mesothelioma may not improve survival or quality of life. The details of this study appeared in the May 17, 2008 issue of The Lancet.
Population-based Epidemiology and Prognosis of Mesothelioma Defined (4/2/2008)
Researchers from Leeds in the UK have reported that the incidence of mesothelioma is increasing and that the prognosis is worse than ascertained in selected studies from referral institutions. The details of this study appeared in an early online publication in Thorax on January 17, 2008.
Comprehensive Approach to Peritoneal Mesothelioma Described (3/26/2008)
Researchers from Columbia University have reported that combined resection, intraperitoneal chemotherapy, and whole abdominal radiation therapy is effective treatment for malignant peritoneal mesothelioma. The details of this study were reported in the February 2008 issue of the American Journal of Clinical Oncology.
Baseline CT Screening Reported Useful for Asbestos Exposed Population (11/21/2007)
Researchers from Italy have reported that CT screening of persons exposed to asbestos is useful for the detection of early lung cancer. The details of this study appeared in the November, 2007 issue of The Oncologist.
Results of Alimta® for Treatment of Malignant Pleural Mesothelioma Reported (10/31/2007)
At the 12th World Conference on Lung Cancer in September, 2007 there were two studies presented on the treatment of malignant mesothelioma with Alimta (pemetrexed).
Alimta®/Platinum-compound Combination Confirmed Active in Mesothelioma (6/28/2007)
According to results recently presented at the 2007 annual meeting of the American Society of Clinical Oncology, the chemotherapy combination consisting of Alimta (pemetrexed) plus a platinum compound (Platinol® [cisplatin] or Paraplatin® [carboplatin]) has been confirmed as an active therapeutic regimen in the treatment of patients with previously untreated malignant pleural mesothelioma.
Onconase® Granted Orphan Drug Status (2/5/2007)
The United States Food and Drug Administration (FDA) has granted Alfacell Corporation orphan drug designation for their agent Onconase (ranpirnase) for the treatment of malignant mesothelioma.
Sequential Chemotherapy for Pleural Mesothelioma Promising (4/20/2006)
Researchers from Italy have reported that sequential chemotherapy with Platinol® (cisplatin) and Gemzar (gemcitabine) followed by Novantrone® (mitoxantrone), methotrexate and Mutamycin® (mitomycin) is an active regimen with good disease control for patients with un-resectable malignant pleural mesothelioma.
Osteopontin Levels May Identify Patients with Early Stage Mesothelioma (10/14/2005)
Researchers from several institutions have reported that serum osteopontin levels can be used to identify persons with asbestos exposure who do or do not have mesothelioma.
Tomudex® Plus Platinol® Improves Survival of Patients with Malignant Pleural Mesothelioma (10/3/2005)
Researchers affiliated with the European Organization for Research and Treatment of Cancer (EORTC) Lung Cancer Group and the National Cancer Institute of Canada have reported that the combination of Tomudex (raltitrexed) and Platinol (cisplatin) improves survival of patients with malignant pleural mesothelioma (MPM) compared to Platinol alone.
European Prognosis Score Validated in Malignant Pleural Mesothelioma (1/31/2005)
A recent article in the Journal of Clinical Oncology reports that the current model for determining the prognosis for malignant pleural mesothelioma (MPM) is a valid tool for determining high and low-risk patients for clinical trial participation.
Gemzar® and Platinol® Neoadjuvant Chemotherapy May Improve Outcome of Pneumonectomy for Mesothelioma (9/16/2004)
Researchers from Switzerland have reported the outcomes of 19 patients with mesothelioma scheduled to be treated with extrapleural pneumonectomy and radiation therapy after neoadjuvant chemotherapy with Gemzar® (gemcitabine) and Platinol® (cisplatin). The details of this report appeared in the September 1, 2004 issue of the Journal of Clinical Oncology.
Alimta® Approved for Mesothelioma (2/5/2004)
The FDA announced today the approval of
Alimta® (pemetrexed) in combination with Platinol® for the treatment of malignant pleural mesothelioma in patients who are not candidates for surgery.
1
Possible Blood Test for Mesothelioma in Development (11/17/2003)
Researchers from the Pacific Northwest Research Institute in Seattle and the University of Western Australia have reported the development of a blood test which may be useful for the diagnosis and monitoring of patients with mesothelioma. The details of this development were published in the November 15, 2003 issue of the
Lancet.
Pemexetred (Altima®) plus Platinol® Extends Survival in Mesothelioma: First Therapy to Make a Difference (7/14/2003)
Patients with cancer of the lining of the lung, known as pleural mesothelioma, live longer and have less pain and shortness of breath when treated with a combination of cisplatin plus a newer drug called pemetrexed than if they received cisplatin alone. These Phase III findings were published in the July 15, 2003, issue of the
Journal of Clinical Oncology.
Doxil®, Paraplatin®, and Gemzar®: An Active Combination for Mesothelioma (6/9/2003)
Researchers affiliated with the Nordic Mesothelioma Group reported that treatment of patients with advanced mesothelioma with a regimen including
Doxil®, Paraplatin® and
Gemzar® resulted in partial response and stabilization rates that compare favorably with other chemotherapy regimens for advanced mesothelioma. This data was presented at the 39th meeting of the American Society of Clinical Oncology in Chicago in June of 2003.
Gemzar® and Paraplatin®: A Well Tolerated Regimen for Advanced Mesothelioma (5/28/2003)
Italian researchers have concluded that the combination of Gemzar® and Paraplatin® provides effective palliation with acceptable toxicity for patients with malignant pleural mesothelioma. (1) They reported their findings in the May 19, 2003 issue of
Cancer.
Combination Raltitrexed and Oxaliplatin is Active for Treatment of Mesothelioma (1/22/2003)
Mesothelioma is regarded as relatively chemo-resistant, but recent studies have shown that significant palliation is possible. Platinol® alone is the standard by which other regimens are judged. There is emerging evidence that combining an antimetabolite with a platinum compound may be the current best approach to treating patients with malignant mesothelioma. One recent study has suggested that the combination of Platinol® and pemetrexed is superior to Platinol® alone. Some patients who have failed to respond to Platinol® will respond to oxaliplatin. Thus, the substitution of oxaliplatin for Platinol® is a reasonable, especially for Platinol®-resistant patients. French researchers have recently performed a relatively large phase II clinical trial evaluating raltitrexed and oxaliplatin for the treatment of patients with malignant mesothelioma.
Lilly Given OK To Make Alimta® (pemetrexed) Available on Expanded Access Basis:Agent Now Available to Medically Eligible Patients With Malignant Pleural Mesothelioma (7/12/2002)
Eli Lilly and Company (NYSE:LLY) and the U.S. Food and Drug Administration have reached agreement to make Alimta® (pemetrexed) available on an expanded access, or compassionate use, basis to medically eligible patients with malignant pleural mesothelioma, a devastating cancer usually associated with exposure to asbestos.
Pemetrexed (Alimta®) Plus Platinol® Proposed as Standard of Care for Patients with Metastatic Mesothelioma (5/23/2002)
Mesothelioma is a relatively rare cancer and when metastatic, has no proven effective standard therapy. There are currently no FDA-approved chemotherapy treatments for this disease. This disease presents as pleural nodules or diffuse involvement of the pleura. From the histological point of view, the epithelial form in general has a better outcome than the sarcomatous form. There are approximately 2,000-3,000 new cases per year in the U.S. and the increase in incidence has stimulated a lot of recent drug trials in attempts to improve outcomes. Because all cases are due to exposure to chronic asbestos exposure, the peak incidence will not occur until sometime between 2010 and 2020. It has been estimated that 250,000 patients will die of this cancer over the next two decades. Action by the U.S. and most European governments stopped the exposure to asbestos 10-20 years ago, which should decrease the incidence. Until recently, clinical trials were hampered by a lack of TMN staging and lack of knowledge about the basic pathogenesis and biology of the cancer. One of the more difficult problems has been to determine the best method for measuring response. This is because clinical evidence of disease is usually thickening of the pleura and abnormal pulmonary function. Recently, it has been proposed that CT scanning showing a 25% reduction constitutes a response to treatment. There has also been more frequent utilization of pulmonary function studies and pain measurements to evaluate responses.
The Combination Oxaliplatin and Raltitrexed is Effective For Treatment of Inoperable Malignant Pleural Mesothelioma: Results of a Pilot Study (5/14/2002)
Italian researchers have recently found that the combination of oxaliplatin and raltitrexed is active against malignant pleural mesothelioma, according to results published in
Tumori.
|
|
Patient Home
